Altaris completes take-private of Simulations Plus
Simulations Plus, the Nasdaq-listed developer of model-informed and AI-accelerated drug development software, announced the completion of its acquisition by affiliates of healthcare-focused investment firm Altaris. The transaction was originally announced on June 16, 2026, and shares of the company were converted at the effective time of the merger.
Why it matters: Another listed life-sciences software name leaves the public markets as healthcare-specialist buyout firms keep hunting for niche, high-margin pharma tools.
Read the full coverage, free
We only link to sources you can read without a subscription. How we check.
Following healthcare M&A?
The next big healthcare deal will be in our email the morning after it's announced, with the rest of the day's biggest deals. Free, with no paywalled links.
See what you get →